Stockscreener 앱 받기
0.051
6.92%
0.0033
시간 외 거래:
.06
0.009
+17.65%
전일 마감가:
$0.0477
열려 있는:
$0.0522
하루 거래량:
345.42M
Relative Volume:
1.82
시가총액:
$309.92K
수익:
-
순이익/손실:
$-33.44M
주가수익비율:
-0.00318
EPS:
-16.0242
순현금흐름:
$-28.30M
1주 성능:
+11.11%
1개월 성능:
-49.00%
6개월 성능:
-95.57%
1년 성능:
-98.29%
1일 변동 폭
$0.0503
$0.055
1주일 범위
$0.0443
$0.0558
52주 변동 폭
$0.0325
$10.79
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
0.051 | 17.52M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-03 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-22 | 개시 | Truist | Buy |
| 2020-07-24 | 개시 | Oppenheimer | Outperform |
| 2019-08-19 | 개시 | H.C. Wainwright | Buy |
| 2018-10-19 | 개시 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | Citigroup | Buy |
| 2017-10-23 | 개시 | Jefferies | Buy |
| 2017-10-23 | 개시 | William Blair | Outperform |
모두보기
Nucana Plc Adr 주식(NCNA)의 최신 뉴스
NCNA’s Market Whiplash: -98.30% YTD Decline, -65.02% Plunge in 30 Days - investchronicle.com
NuCana (NCNA) Announces 1-for-200 Reverse ADS Split Effective Aug 8 2025 - Stock Titan
NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com
NuCana CEO takes leave of absence due to health reasons - Investing.com
Market Insight: RxSight Inc (RXST)’s Notable Drop, Closing at 13.50 - DWinneX
The Future of NuCana plc ADR: Analyzing NCNA - investchronicle.com
nucana plc announces annual report release and upcoming agm - Investing.com India
NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
NuCana prices $7 million direct offering of ADSs and warrants By Investing.com - Investing.com India
New Outlook On NuCana plc ADR - Stocksregister
NCNA’s Stock Journey: What Investors Need to Know About NuCana plc ADR’s Performance - investchronicle.com
Do investors need to be concerned about Cadiz Inc (CDZI)? - uspostnews.com
Natera Inc (NTRA) deserves closer scrutiny - uspostnews.com
Weave Communications Inc (WEAV) produces promising results - uspostnews.com
Investing in NuCana plc ADR (NCNA) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
Post-Trade Analysis: NuCana plc ADR (NCNA) Slides -26.97, Closing at 0.65 - DWinneX
Closing Bell Recap: Yxt.Com Group Holding Ltd. ADR (YXT) Ends at 0.56, Reflecting a -14.42 Downturn - DWinneX
In the Green: Gogoro Inc (GGR) Closes at 0.26, Up/Down 0.08 from Previous Day - DWinneX
Daily Market Movement: Tivic Health Systems Inc (TIVC) Sees a 1.88 Increase, Closing at 7.04 - DWinneX
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Barchart.com
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NuCana stock downgraded by William Blair after halted cancer study - Investing.com
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana regains Nasdaq compliance with bid price rule - Investing.com
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
NuCana plcADR (NCNA) Price Target Increased by 15.39% to 5.10 - Nasdaq
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Nasdaq
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Nasdaq
Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Nasdaq
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo Finance
Cboe U.S. Equities Exchanges Overview - Cboe Global Markets
Will NuCana Continue to Surge Higher? - Nasdaq
NuCana (NCNA) Stock Price, News & Analysis - MarketBeat
NCNA Stock Price and Chart — NASDAQ:NCNA - TradingView
NuCana PLC Stock Price Today | NASDAQ: NCNA Live - Investing.com
Nucana Plc Adr (NCNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):